Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.
Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influence on cardiovascular disease and drugs used in the control of cardiovascular risk factors showing a beneficial effect on the liver disease will be reviewed.
Unidad de Lípidos, Servicio de Medicina Interna, Hospital San Pedro, Logroño, España. Electronic address: abrea@riojasalud.es.
Ángel
Á
Brea
Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Idibell, CiberObn, L'Hospitalet de Llobregat, Barcelona, España.
Xavier
X
Pintó
Servicio de Endocrinología, Hospital Clínico, Valencia, España.
Juan F
JF
Ascaso
Área Sanitaria de Delicias, Atención Primaria, Zaragoza, España.
Mariano
M
Blasco
Centro de Salud de Bembibre, Bembibre, León, España.
Ángel
Á
Díaz
Departamento de Medicina, Universidad de Málaga, Málaga, España.
Pedro
P
González-Santos
Servicio de Endocrinología, Hospital Universitario Dr. Peset, Universitat de València, Valencia, España.
Antonio
A
Hernández-Mijares
Centro de Salud de Prosperidad, Atención Primaria, Madrid, España.
Teresa
T
Mantilla
Unidad de Lípidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España.
Jesús
J
Millán
Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España.
Juan
J
Pedro-Botet
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology* / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications* / Q000628:therapy; D012307:Risk Factors
Arteriosclerosis; Cardiovascular diseases; Cardiovascular risk; Enfermedad del hígado graso no alcohólica; Enfermedades cardiovasculares; Esteatohepatitis no alcohólica; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Riesgo cardiovascular; Tratamiento; Treatment